Back to Faculty
Consultant

Peter Weiden

MD
Clinical Professor of Psychiatry
Stony Brook University

Peter J. Weiden, M.D.
Clinical Professor of Psychiatry at Stony Brook University
Principal Investigator, CNS clinical trials, Richmond Behavioral Associates (RBA)

Peter J. Weiden MD has devoted his professional career to improving clinical outcomes for people with schizophrenia. He received his MD at SUNY Stony Brook and his psychiatry residency at New York Hospital-Cornell Medical Center. During residency he developed expertise in drug-induced movement disorders, ultimately becoming Editor-in-Chief of the DSM-IV section on drug-induced movement disorders. His early research career included other aspects of treatment of schizophrenia including relapse prevention and CBT adapted for psychotic disorders. Dr. Weiden established comprehensive programs for schizophrenia and other serious disorders at four academic medical centers, including New York Hospital/Cornell and St Luke’s/Roosevelt Hospital Center in Manhattan, SUNY Downstate Medical Center in Brooklyn, and UIC Medical Center in Chicago.

In 2016 Dr. Weiden joined the pharmaceutical company Alkermes to focus on new drug development for schizophrenia and bipolar disorder, including clinical development of the LAI aripiprazole lauroxil (ARISTADA) and an oral combination of olanzapine/samidorphan approved as Lybalvi. From 2020-2023 he joined Karuna Therapeutics’ Phase 3 clinical program on the novel muscarinic activator KarXT (now COBENFY). In 2023 Dr. Weiden returned to academic teaching at SUNY Stony Brook and as a principal investigator of new drug development for mental health indications at Richmond Behavioral Associates located in Staten Island, New York.

2026 Sessions

Long-Acting Injectables: When, Why, and How to Get Better Outcomes

Despite strong evidence supporting their use, long-acting injectable antipsychotics remain underutilized in clinical practice. This session reviews patient selection, the pharmacologic principles behind LAIs, and practical approaches to initiating and integrating these therapies into routine care. Learners will gain clinical pearls for overcoming common barriers and optimizing treatment outcomes.

Speaker

Saturday, November 14 11:40–12:40 PM
Room Salon 1 - 2
Program Chair

Ilan Melnick

MD
Chief Medical Officer, Passageway Residences of Dade County,
Passageway Residences of Dade County

Ilan Melnick, MD, is the primary psychiatrist in two outpatient clinics in the Miami, Florida area, as well as a staff psychiatrist and Chief Medical Officer at Passageway Residences of Miami-Dade County. In addition, Dr. Melnick is a staff psychiatrist and Medical Director for Jewish Community Services and performs independent medical and psychiatric evaluations for Miami-Dade County police, fire, transit and aviation departments.

Dr. Melnick received his medical degree in Bayamon, Puerto Rico and went on to do his residency in psychiatry and fellowship in geriatric psychiatry at the University of Miami/Jackson Memorial Hospital.He continues to be involved in education as an Assistant Professor at Florida International University School of medicine. He continues to be involved in education through his role giving grand rounds at major universities and hospitals around the world.

Consultant

Peter Weiden

MD
Clinical Professor of Psychiatry
Stony Brook University

Peter J. Weiden, M.D.
Clinical Professor of Psychiatry at Stony Brook University
Principal Investigator, CNS clinical trials, Richmond Behavioral Associates (RBA)

Peter J. Weiden MD has devoted his professional career to improving clinical outcomes for people with schizophrenia. He received his MD at SUNY Stony Brook and his psychiatry residency at New York Hospital-Cornell Medical Center. During residency he developed expertise in drug-induced movement disorders, ultimately becoming Editor-in-Chief of the DSM-IV section on drug-induced movement disorders. His early research career included other aspects of treatment of schizophrenia including relapse prevention and CBT adapted for psychotic disorders. Dr. Weiden established comprehensive programs for schizophrenia and other serious disorders at four academic medical centers, including New York Hospital/Cornell and St Luke’s/Roosevelt Hospital Center in Manhattan, SUNY Downstate Medical Center in Brooklyn, and UIC Medical Center in Chicago.

In 2016 Dr. Weiden joined the pharmaceutical company Alkermes to focus on new drug development for schizophrenia and bipolar disorder, including clinical development of the LAI aripiprazole lauroxil (ARISTADA) and an oral combination of olanzapine/samidorphan approved as Lybalvi. From 2020-2023 he joined Karuna Therapeutics’ Phase 3 clinical program on the novel muscarinic activator KarXT (now COBENFY). In 2023 Dr. Weiden returned to academic teaching at SUNY Stony Brook and as a principal investigator of new drug development for mental health indications at Richmond Behavioral Associates located in Staten Island, New York.
Back to top